{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:15:46Z","timestamp":1787883346427,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fruquintinib, a highly selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1\u20133, has demonstrated significant survival benefits in metastatic colorectal cancer (mCRC). While pivotal clinical trials have characterized its general toxicity profile, the molecular mechanisms driving specific, high-risk adverse events in the real-world setting remain underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We adopted a \u201cbedside-to-bench\u201d reverse translational strategy to systematically evaluate the safety profile of Fruquintinib. First, we analyzed spontaneous reports from the FDA Adverse Event Reporting System (FAERS) (Q4 2023\u2013Q1 2025) using disproportionality algorithms (ROR, PRR, BCPNN, and MGPS) to detect significant safety signals. Recognizing proteinuria as a clinically critical organ-specific toxicity, we subsequently prioritized it for mechanistic investigation. A \u201cdrug-target-disease\u201d network was constructed, followed by molecular docking and 100-nanosecond (ns) molecular dynamics (MD) simulations to elucidate the underlying molecular etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,632 Fruquintinib-related reports were identified, with 66.2% of adverse events occurring within the first 30 days of therapy. Significant disproportionality signals were detected for myelosuppression (ROR = 29.31, 95% CI: 23.40\u201336.71), dysphonia (ROR = 21.96, 95% CI: 18.37\u201326.26), and proteinuria (ROR = 16.92, 95% CI: 11.81\u201324.23). Network pharmacology analysis mapped the intersection of drug and disease targets, identifying SRC and STAT3 as core hub kinases. Molecular docking revealed that Fruquintinib exhibits favorable theoretical binding affinities to the active pockets of SRC (\u22127.8\u00a0kcal\/mol) and STAT3 (\u22127.4\u00a0kcal\/mol), surpassing its affinity for several canonical targets. MD simulations further confirmed the rigorous dynamic stability of these complexes (RMSD \u223c0.22\u00a0nm) and revealed a distinct induced-fit binding mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides the first integration of pharmacovigilance data with biophysical modeling for Fruquintinib. Beyond corroborating established class related safety profiles, we hypothesize a novel dual hit molecular framework for renal toxicity. This clinical association might involve both classical vascular endothelial growth factor receptor blockade and the potential off target structural interactions of SRC and STAT3. These insights underscore the importance of early renal monitoring and offer structural insights into the drug\u2019s safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1796154","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:48:33Z","timestamp":1773384513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world pharmacovigilance and molecular mechanisms of fruquintinib: SRC and STAT3 as potential off-target mediators of proteinuria"],"prefix":"10.3389","volume":"17","author":[{"given":"Duogang","family":"Xu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Trauma Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Chinese Integrative Medicine Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Department of Urology, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Central Laboratory of Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Central Laboratory of Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichun","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Central Laboratory of Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfa","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Department of Pathology, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youtao","family":"Guan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Department of Pathology, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]},{"name":"Department of Pathology, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Yan\u2019an Hospital Affiliated to Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN guidelines insights: Colon cancer, version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/17512433.2019.1630272","article-title":"The clinical application of fruquintinib on colorectal cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04662","article-title":"Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12916-025-04159-y","article-title":"Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial","volume":"23","author":"Kan","year":"2025","journal-title":"BMC Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s10555-012-9357-9","article-title":"Quality of life and supportive care for patients with metastatic renal cell carcinoma","volume":"31","author":"Lambea","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","article-title":"Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care","volume":"36","author":"Lankheet","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"sfaf394","DOI":"10.1093\/ckj\/sfaf394","article-title":"Biopsy-proven tyrosine kinase inhibitor-associated renal injury: a case series","volume":"19","author":"Lian","year":"2026","journal-title":"Clin. Kidney J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1517\/17460441.2014.924923","article-title":"The preclinical development of regorafenib for the treatment of colorectal cancer","volume":"9","author":"Miura","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17425255.2024.2332364","article-title":"Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer","volume":"20","author":"Patell","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/biomedicines11082311","article-title":"Renal disorders with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA adverse event reporting system database","volume":"11","author":"Russo","year":"2023","journal-title":"Biomedicines"},{"key":"B19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.3390\/cancers14215315","article-title":"Safety of anti-angiogenic drugs in pediatric patients with solid tumors: a systematic review and meta-analysis","volume":"14","author":"Spini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2590283","DOI":"10.1080\/0886022X.2025.2590283","article-title":"Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors","volume":"47","author":"Tian","year":"2025","journal-title":"Ren. Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1172\/JCI27414","article-title":"Nephrin ectodomain engagement results in src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization","volume":"116","author":"Verma","year":"2006","journal-title":"J. Clin. Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"156220","DOI":"10.1016\/j.phymed.2024.156220","article-title":"The inhibition of rutin on Src kinase blocks high glucose-induced EGFR\/ERK transactivation in diabetic nephropathy by integrative approach of network pharmacology and experimental verification","volume":"135","author":"Wu","year":"2024","journal-title":"Phytomedicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2353\/ajpath.2007.070075","article-title":"Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes","volume":"171","author":"Yanagida-Asanuma","year":"2007","journal-title":"Am. J. Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12328-024-02087-7","article-title":"Evaluation of fruquintinib's efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials","volume":"18","author":"Yonatan","year":"2025","journal-title":"Clin. J. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e28132","DOI":"10.1016\/j.heliyon.2024.e28132","article-title":"Novel insights into post-marketing adverse events associated with lenvatinib: a comprehensive analysis utilizing the FAERS database","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"B34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14740338.2023.2284989","article-title":"Newly identified adverse events for gemcitabine using the food and drug administration adverse event reporting system","volume":"23","author":"Zhang","year":"2024","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1796154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:48:34Z","timestamp":1773384514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1796154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1796154"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1796154","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1796154"}}